The Entrapment of Paclitaxel in PLGA Nanoparticles Increases its Cytotoxicity against Multiresistant Cell Line

Vanya, Bojat,

doi:10.9734/bjmmr/2011/382

Cited by 10 publications

(5 citation statements)

References 27 publications

(27 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…An EE higher than 85% was observed for formulations with 50 to 90 μg of PTX, while for 100 µg, the loss of PTX was high, decreasing the EE to 74% ( Table 1 ). These results agree with previously reported data by Bojat et al, who found that PTX:PLGA ratios below 1:100 ensured a low drug loss [ 21 ]. Based on our results, it can be concluded that the formulation obtained using 80 μg of PTX may be considered as optimal for the development of the chemo-photothermal therapy system.…”

Section: Resultssupporting

confidence: 93%

Gold Half-Shell-Coated Paclitaxel-Loaded PLGA Nanoparticles for the Targeted Chemo-Photothermal Treatment of Cancer

et al. 2023

View full text Add to dashboard Cite

Conventional cancer therapies suffer from nonspecificity, drug resistance, and a poor bioavailability, which trigger severe side effects. To overcome these disadvantages, in this study, we designed and evaluated the in vitro potential of paclitaxel-loaded, PLGA-gold, half-shell nanoparticles (PTX-PLGA/Au-HS NPs) conjugated with cyclo(Arg-Gly-Asp-Phe-Lys) (cyRGDfk) as a targeted chemo-photothermal therapy system in HeLa and MDA-MB-231 cancer cells. A TEM analysis confirmed the successful gold half-shell structure formation. High-performance liquid chromatography showed an encapsulation efficiency of the paclitaxel inside nanoparticles of more than 90%. In the release study, an initial burst release of about 20% in the first 24 h was observed, followed by a sustained drug release for a period as long as 10 days, reaching values of about 92% and 49% for NPs with and without near infrared laser irradiation. In in vitro cell internalization studies, targeted nanoparticles showed a higher accumulation than nontargeted nanoparticles, possibly through a specific interaction of the cyRGDfk with their homologous receptors, the ανβ3 y ανβ5 integrins on the cell surface. Compared with chemotherapy or photothermal treatment alone, the combined treatment demonstrated a synergistic effect, reducing the cell viability to 23% for the HeLa cells and 31% for the MDA-MB-231 cells. Thus, our results indicate that these multifuncional nanoparticles can be considered to be a promising targeted chemo-photothermal therapy system against cancer.

show abstract

Section: Resultssupporting

confidence: 93%

Gold Half-Shell-Coated Paclitaxel-Loaded PLGA Nanoparticles for the Targeted Chemo-Photothermal Treatment of Cancer

et al. 2023

View full text Add to dashboard Cite

show abstract

“…This strong improvement was hypothesized to be due to a significant internalization of these nano-objects in both glioma cells compared to the free formulation. 38 However, in the F98 cell line, the effect was even more spectacular, with a PF of 50 for PLGA and 100 for PLGA/P188 Teva V R -loaded NPs. An increase in the cytotoxicity of encapsulated etoposide has already been reported by others, 17 but to our knowledge, this was the first time that such a huge difference was observed.…”

Section: Discussionmentioning

confidence: 99%

Etoposide encapsulation in surface‐modified poly(lactide‐co‐glycolide) nanoparticles strongly enhances glioma antitumor efficiency

Callewaert

Dukic

Gulick

et al. 2012

J Biomedical Materials Res

View full text Add to dashboard Cite

Etoposide (VP-16) is a hydrophobic anticancer agent inhibiting Topoisomerase II, commonly used in pediatric brain chemotherapeutic schemes as mildly toxic. Unfortunately, despite its appropriate solubilization in vehicle solvents, its poor bioavailability and limited passage of the blood-brain barrier concur to disappointing results requiring the development of new delivery system forms. In this study, etoposide formulated as a parenteral injectable solution (Teva®) was loaded into all-biocompatible poly(lactide-co-glycolide) (PLGA) or PLGA/P188-blended nanoparticles (size 110-130 nm) using a fully biocompatible nanoprecipitation technique. The presence of coprecipitated P188 on encapsulation efficacies and in vitro drug release was investigated. Drug encapsulation was determined using HPLC. Inflammatory response was checked by FACS analysis on human monocytes. Cytotoxic activity of the various simple (Teva®) or double (Teva®-loaded NPs) formulations was studied on the murine C6 and F98 cell lines. Obtained results suggest that, although noninflammatory neither nontoxic by themselves, the use of PLGA and PLGA/P188 nanoencapsulations over pre-existing etoposide formulation could induce a greatly improved cytotoxic activity. This approach demonstrated a promising perspective for parenteral delivery of VP16 and potential development of a therapeutic entity.

show abstract

“…10,11 Among biodegradable and biocompatible nanoparticles, poly(lactic-co-glycolic acid) (PLGA) nanoparticles, which are designed to target cancer cells, have been proven to improve the pharmacological and therapeutic properties of drugs and extensively used for drug delivery. [12][13][14][15][16][17][18][19][20][21] Among these studies, Herceptin (HER; Trastuzumab) was used as targeting ligand on PLGA nanoparticles for breast cancer targeting. 13,19,21 HER is approved as an antibody for the treatment of human epidermal growth factor receptor type 2 (HER2)-positive metastatic breast cancers, and the receptor is overexpressed in 25-30% of the invasive breast cancers.…”

Section: Introductionmentioning

confidence: 99%

Herceptin‐decorated salinomycin‐loaded nanoparticles for breast tumor targeting

Aydın

2012

J Biomedical Materials Res

View full text Add to dashboard Cite

The use of conventional chemotherapeutic drugs was emerged as challenging for breast cancer therapy, because breast cancer stem cells cannot be destroyed due to their great nature of drug resistance. In this study, a novel nanoparticulate system of Herceptin (HER)-immobilized salinomycin (SAL)-encapsulated poly(lactic-co-glycolic acid) (PLGA) (HER-SAL-PLGA) nanoparticles were constructed and investigated for breast cancer targeting. SAL-encapsulated PLGA nanoparticles were characterized for their particle size, morphology, structural and thermal properties, and drug-encapsulation efficiency. HER-SAL-PLGA nanoparticles were characterized via particle size, surface chemistry, and herceptin-immobilization efficiency. In vitro release studies were performed for both nontargeting and targeting SAL-PLGA nanoparticles, which demonstrated a controlled release of SAL from nanoparticles. Cellular uptake of the HER-SAL-PLGA nanoparticles was assessed by fluorescence and optical microscopy and flow cytometry, which showed that the HER-SAL-PLGA nanoparticles were successfully uptaken by MCF7 cells. In conclusion, this novel drug-delivery system, HER-SAL-PLGA, was suggested as a promising targeting system for breast cancer therapy.

show abstract

The Entrapment of Paclitaxel in PLGA Nanoparticles Increases its Cytotoxicity against Multiresistant Cell Line

Cited by 10 publications

References 27 publications

Gold Half-Shell-Coated Paclitaxel-Loaded PLGA Nanoparticles for the Targeted Chemo-Photothermal Treatment of Cancer

Gold Half-Shell-Coated Paclitaxel-Loaded PLGA Nanoparticles for the Targeted Chemo-Photothermal Treatment of Cancer

Etoposide encapsulation in surface‐modified poly(lactide‐co‐glycolide) nanoparticles strongly enhances glioma antitumor efficiency

Herceptin‐decorated salinomycin‐loaded nanoparticles for breast tumor targeting

Contact Info

Product

Resources

About